Your browser doesn't support javascript.
loading
Berberine nanostructures attenuate ß-catenin, a key component of epithelial mesenchymal transition in lung adenocarcinoma.
Malyla, Vamshikrishna; De Rubis, Gabriele; Paudel, Keshav Raj; Chellappan, Dinesh Kumar; Hansbro, Nicole G; Hansbro, Philip M; Dua, Kamal.
Afiliación
  • Malyla V; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • De Rubis G; Centre for Inflammation, Centenary Institute, Sydney, Sydney, NSW, 2050, Australia.
  • Paudel KR; Australian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
  • Chellappan DK; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • Hansbro NG; Australian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
  • Hansbro PM; Centre for Inflammation, Centenary Institute, Sydney, Sydney, NSW, 2050, Australia.
  • Dua K; Faculty of Science, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Naunyn Schmiedebergs Arch Pharmacol ; 396(12): 3595-3603, 2023 12.
Article en En | MEDLINE | ID: mdl-37266589
Lung cancer (LC) is the leading cause of cancer-related deaths globally. It accounts for more than 1.9 million cases each year due to its complex and poorly understood molecular mechanisms that result in unregulated cell proliferation and metastasis. ß-Catenin is a developmentally active protein that controls cell proliferation, metastasis, polarity and cell fate during homeostasis and aids in cancer progression via epithelial-mesenchymal transition. Therefore, inhibition of the ß-catenin pathway could attenuate the progression of LC. Berberine, an isoquinoline alkaloid which is known for its anti-cancer and anti-inflammatory properties, demonstrates poor solubility and bioavailability. In our study, we have encapsulated berberine into liquid crystalline nanoparticles to improve its physiochemical functions and studied if these nanoparticles target the ß-catenin pathway to inhibit the human lung adenocarcinoma cell line (A549) at both gene and protein levels. We observed for the first time that berberine liquid crystalline nanoparticles at 5 µM significantly attenuate the expression of the ß-catenin gene and protein. The interaction between berberine and ß-catenin was further validated by molecular simulation studies. Targeting ß-catenin with berberine nanoparticles represents a promising strategy for the management of lung cancer progression.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Berberina / Nanoestructuras / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Naunyn Schmiedebergs Arch Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Berberina / Nanoestructuras / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Naunyn Schmiedebergs Arch Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Alemania